{"id":"sars-cov-2-vaccine","safety":{"commonSideEffects":[{"rate":"40-70","effect":"Injection site pain or swelling"},{"rate":"20-50","effect":"Fatigue"},{"rate":"20-50","effect":"Headache"},{"rate":"20-40","effect":"Myalgia"},{"rate":"10-30","effect":"Fever"},{"rate":"5-20","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SARS-CoV-2 vaccines work by stimulating both humoral (antibody) and cellular (T-cell) immune responses against the virus. Depending on the platform (mRNA, viral vector, protein subunit, or inactivated virus), the vaccine either delivers genetic material encoding the spike protein or the protein itself, enabling the body to mount a protective immune response before natural infection occurs.","oneSentence":"This vaccine trains the immune system to recognize and attack SARS-CoV-2 virus by presenting viral antigens or genetic instructions to produce them.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:52.548Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 infection and severe disease"}]},"trialDetails":[{"nctId":"NCT06585241","phase":"PHASE4","title":"A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-09","conditions":"SARS-CoV-2","enrollment":1144},{"nctId":"NCT07221162","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-12-05","conditions":"COVID-19","enrollment":140},{"nctId":"NCT07183709","phase":"PHASE1","title":"Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-02-02","conditions":"COVID-19","enrollment":60},{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT05392075","phase":"","title":"COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2023-03-15","conditions":"COVID-19 Pneumonia, COVID-19","enrollment":100},{"nctId":"NCT05283902","phase":"","title":"Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly","status":"COMPLETED","sponsor":"Federal University of Espirito Santo","startDate":"2022-03-19","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases","enrollment":260},{"nctId":"NCT04649021","phase":"PHASE2","title":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-12-04","conditions":"SARS-CoV-2","enrollment":960},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT05765773","phase":"PHASE2","title":"An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2021-07-01","conditions":"Corona Virus Infection, Vaccine, COVID-19","enrollment":200},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":"COVID-19","enrollment":285000},{"nctId":"NCT07473986","phase":"","title":"REAl LIfe\" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-07-08","conditions":"SARS-CoV-2 Omicron Variants","enrollment":88},{"nctId":"NCT05876377","phase":"","title":"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome","enrollment":1},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT06181292","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-11-15","conditions":"SARS-CoV2 Infection","enrollment":913},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06848309","phase":"","title":"Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host","enrollment":300},{"nctId":"NCT05142553","phase":"PHASE2","title":"Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2021-11-16","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":887},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT07096245","phase":"NA","title":"Conectados: Social Networks and Social Media for Vaccine Uptake","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2025-09-10","conditions":"Vaccination","enrollment":507},{"nctId":"NCT05672355","phase":"PHASE2","title":"A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"Chronic Lymphocytic Leukemia, COVID-19 Infection","enrollment":80},{"nctId":"NCT07051031","phase":"PHASE4","title":"COVID-19 Reactogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marcel Curlin","startDate":"2025-10-01","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04992195","phase":"","title":"Impact of COVID-19 Vaccines on Cerebrovascular Health","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2021-07-05","conditions":"Stroke, Stroke, Acute, Stroke, Ischemic","enrollment":500},{"nctId":"NCT05415267","phase":"PHASE3","title":"Immunosuppression and COVID-19 Boosters","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2023-07-21","conditions":"COVID-19","enrollment":320},{"nctId":"NCT07416539","phase":"PHASE1","title":"Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19","status":"RECRUITING","sponsor":"Rokote Laboratories Finland Oy","startDate":"2026-02-10","conditions":"COVID - 19, SARS CoV-2","enrollment":20},{"nctId":"NCT06505993","phase":"NA","title":"Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia","status":"SUSPENDED","sponsor":"Marc Kiviniemi","startDate":"2026-09","conditions":"COVID-19, Vaccine Hesitancy","enrollment":2250},{"nctId":"NCT06181656","phase":"","title":"Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-02-05","conditions":"Pneumococcal Vaccine, Esophageal Cancer, Lymphopenia","enrollment":80},{"nctId":"NCT04839146","phase":"PHASE1","title":"Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-03-11","conditions":"Covid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection","enrollment":45},{"nctId":"NCT07079670","phase":"PHASE3","title":"Safety and Immunogenicity of NVX-CoV2705","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-10-09","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":676},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT07280858","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-01-28","conditions":"Healthy Participants, Sarbecovirus","enrollment":368},{"nctId":"NCT04977024","phase":"PHASE2","title":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GeoVax, Inc.","startDate":"2021-09-27","conditions":"COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia","enrollment":63},{"nctId":"NCT07222384","phase":"PHASE3","title":"A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":343},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT04639466","phase":"PHASE1, PHASE2","title":"A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection","status":"COMPLETED","sponsor":"GeoVax, Inc.","startDate":"2020-11-19","conditions":"COVID-19 Infection","enrollment":119},{"nctId":"NCT07390968","phase":"PHASE2","title":"Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-09-01","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":56},{"nctId":"NCT07095231","phase":"PHASE1","title":"Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-08-11","conditions":"COVID-19","enrollment":60},{"nctId":"NCT05119855","phase":"PHASE3","title":"Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-28","conditions":"Papillomavirus Infections, Coronavirus Disease (COVID-19)","enrollment":165},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06065176","phase":"PHASE4","title":"The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection","status":"COMPLETED","sponsor":"Sarang K. Yoon, DO, MOH","startDate":"2023-11-22","conditions":"COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection","enrollment":1188},{"nctId":"NCT05046002","phase":"","title":"COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-08-11","conditions":"Myocarditis, Pericarditis","enrollment":400},{"nctId":"NCT06381739","phase":"PHASE2","title":"A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-03-25","conditions":"COVID-19 Infection","enrollment":350},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT06036134","phase":"NA","title":"Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents","status":"COMPLETED","sponsor":"Arizona State University","startDate":"2023-12-01","conditions":"Vaccine-Preventable Diseases, COVID-19 Pandemic, Health-Related Behavior","enrollment":80},{"nctId":"NCT05951920","phase":"NA","title":"Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-05","conditions":"COVID-19","enrollment":12},{"nctId":"NCT05078905","phase":"","title":"Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"COVID-19, Vaccination, Healthy Volunteer","enrollment":1200},{"nctId":"NCT06074237","phase":"NA","title":"Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters","status":"COMPLETED","sponsor":"Corewell Health East","startDate":"2024-04-25","conditions":"Vaccine Refusal, Vaccine-Preventable Diseases, Physician-Patient Relations","enrollment":112},{"nctId":"NCT06547814","phase":"NA","title":"COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists: A Stepped-Wedge Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-08-05","conditions":"COVID-19","enrollment":20},{"nctId":"NCT06108076","phase":"EARLY_PHASE1","title":"Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-01-16","conditions":"Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction","enrollment":10},{"nctId":"NCT06026514","phase":"PHASE1","title":"Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-09-18","conditions":"SARS-CoV-2 Infection","enrollment":27},{"nctId":"NCT04869592","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2021-04-25","conditions":"COVID-19","enrollment":3100},{"nctId":"NCT05408312","phase":"PHASE1","title":"Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2022-06-18","conditions":"COVID-19 Pneumonia","enrollment":234},{"nctId":"NCT06503900","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-12","conditions":"Birth Outcomes, Safety, Adverse Event Following Immunization","enrollment":98},{"nctId":"NCT05160636","phase":"","title":"A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-01-31","conditions":"COVID-19, Coronavirus Disease 2019, Influenza","enrollment":999},{"nctId":"NCT05766189","phase":"NA","title":"Wastewater Surveillance to Boost COVID-19 Vaccine Uptake","status":"COMPLETED","sponsor":"Syracuse University","startDate":"2023-03-01","conditions":"Vaccination, Wastewater Surveillance","enrollment":100000},{"nctId":"NCT05926544","phase":"NA","title":"COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-10-04","conditions":"COVID-19","enrollment":16},{"nctId":"NCT07341321","phase":"","title":"SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Graz","startDate":"2026-01","conditions":"mRNA Vaccination, Hepatocellular Carcinoma, Checkpoint Inhibitor","enrollment":200},{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-11-08","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":383},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT04872738","phase":"","title":"Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-05-07","conditions":"Breast Cancer Related Lymphedema, Covid19","enrollment":714},{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT05172011","phase":"","title":"Understanding the Long-term Impact of COVID on Children and Families","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-03-01","conditions":"SARS-CoV-2 Infection","enrollment":15028},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT04750720","phase":"NA","title":"Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2020-08-27","conditions":"Covid19, SARS-CoV-2","enrollment":187},{"nctId":"NCT06374394","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":841},{"nctId":"NCT04760704","phase":"","title":"Covid-19 Vaccine Response in Elderly Subjects","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2021-02-18","conditions":"Covid19 Vaccine","enrollment":264},{"nctId":"NCT05919472","phase":"NA","title":"Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women","status":"COMPLETED","sponsor":"Nicole Stoffel","startDate":"2023-07-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT07300839","phase":"PHASE3","title":"A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-12-10","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":25500},{"nctId":"NCT04952766","phase":"PHASE4","title":"Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2021-03-26","conditions":"Kidney Transplant, Myeloma, Cancer","enrollment":196},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT07069309","phase":"PHASE3","title":"A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2025-07-08","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":760},{"nctId":"NCT05228275","phase":"","title":"Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-04-08","conditions":"COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":549},{"nctId":"NCT04852289","phase":"","title":"A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute on Aging (NIA)","startDate":"2021-04-20","conditions":"COVID-19","enrollment":78},{"nctId":"NCT07085611","phase":"NA","title":"Neutralizing Power of Serum Antibodies - 2","status":"RECRUITING","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2025-08-22","conditions":"COVID-19, SARS-CoV-2 Viraemia, Monkey Pox","enrollment":30},{"nctId":"NCT05096091","phase":"","title":"International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-16","conditions":"COVID-19","enrollment":5399},{"nctId":"NCT06821126","phase":"PHASE1, PHASE2","title":"Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-05-09","conditions":"Healthy","enrollment":238},{"nctId":"NCT07287137","phase":"PHASE4","title":"Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-11-12","conditions":"COVID -19, COVID - 19, COVID 19","enrollment":54},{"nctId":"NCT05234372","phase":"NA","title":"MiVacunaLA: an Intervention to Improve COVID-19 Vaccination Behaviors Among Latinos","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2022-06-01","conditions":"COVID-19 Pandemic","enrollment":468},{"nctId":"NCT06436911","phase":"PHASE1, PHASE2","title":"To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA","status":"COMPLETED","sponsor":"Entos Pharmaceuticals Inc.","startDate":"2024-07-22","conditions":"COVID-19","enrollment":46},{"nctId":"NCT06469788","phase":"NA","title":"Testimonials and Navigation in Rheumatology","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2024-12-18","conditions":"Rheumatologic Disease, Autoimmune Diseases","enrollment":1170},{"nctId":"NCT06279871","phase":"PHASE3","title":"Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-03-27","conditions":"COVID-19","enrollment":1514},{"nctId":"NCT04939519","phase":"NA","title":"SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-03-29","conditions":"Covid19","enrollment":65300},{"nctId":"NCT06851611","phase":"PHASE1","title":"The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus","status":"COMPLETED","sponsor":"Rokote Laboratories Finland Oy","startDate":"2025-01-21","conditions":"COVID19, Sars-Cov-2","enrollment":40},{"nctId":"NCT05655351","phase":"EARLY_PHASE1","title":"Effect of a Vaccination Against COVID-19 on Monocyte Production of Oxygenated Derivatives.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-12-21","conditions":"CORONAVIRUS INFECTIONS","enrollment":30},{"nctId":"NCT04780659","phase":"PHASE4","title":"COVID-19 Vaccination of Immunodeficient Persons (COVAXID)","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2021-02-23","conditions":"Covid19","enrollment":539},{"nctId":"NCT06831786","phase":"EARLY_PHASE1","title":"Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2024-03-01","conditions":"COVID - 19","enrollment":36},{"nctId":"NCT06178991","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-12-20","conditions":"Influenza, COVID-19","enrollment":8795},{"nctId":"NCT06694389","phase":"PHASE3","title":"Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-11-18","conditions":"COVID-19, Influenza","enrollment":2457},{"nctId":"NCT04659759","phase":"","title":"COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2020-11-17","conditions":"Covid19","enrollment":105},{"nctId":"NCT05543993","phase":"","title":"COVID Booster in Pregnancy and Lactation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-09-29","conditions":"COVID-19","enrollment":150},{"nctId":"NCT06731127","phase":"","title":"Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People With HIV","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2021-04-10","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT05212948","phase":"PHASE3","title":"A Study of S-268019 for the Prevention of COVID-19","status":"COMPLETED","sponsor":"Shionogi","startDate":"2021-12-25","conditions":"SARS-CoV-2","enrollment":9902},{"nctId":"NCT07254442","phase":"","title":"Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing","status":"COMPLETED","sponsor":"Zonguldak Bulent Ecevit University","startDate":"2021-12-01","conditions":"Hearing, COVID - 19, Ototoxicity","enrollment":90},{"nctId":"NCT04830046","phase":"","title":"Covid-19 Vaccine Responsiveness in MM and Waldenstrom","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-04-15","conditions":"Multiple Myeloma, Waldenstrom Macroglobulinemia, Immune System Disorder","enrollment":146},{"nctId":"NCT05584202","phase":"PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-30","conditions":"SARS-CoV-2","enrollment":68},{"nctId":"NCT05164016","phase":"","title":"Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-06-29","conditions":"Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer","enrollment":21},{"nctId":"NCT05168813","phase":"PHASE2, PHASE3","title":"Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern","status":"COMPLETED","sponsor":"COVID-19 Prevention Network","startDate":"2021-12-01","conditions":"SARS-CoV-2 Infection, HIV Infections, COVID-19","enrollment":14237}],"_emaApprovals":[],"_faersSignals":[{"count":41,"reaction":"COVID-19"},{"count":38,"reaction":"OFF LABEL USE"},{"count":17,"reaction":"PAIN"},{"count":16,"reaction":"NEUTROPENIA"},{"count":16,"reaction":"PNEUMONIA"},{"count":15,"reaction":"DRUG INEFFECTIVE"},{"count":14,"reaction":"ANAEMIA"},{"count":14,"reaction":"NAUSEA"},{"count":13,"reaction":"ARTHRALGIA"},{"count":13,"reaction":"DIARRHOEA"}],"_approvalHistory":[],"publicationCount":3373,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["mRNA-1273"],"phase":"phase_3","status":"active","brandName":"SARS-CoV-2 Vaccine","genericName":"SARS-CoV-2 Vaccine","companyName":"Hospitales Universitarios Virgen del Rocío","companyId":"hospitales-universitarios-virgen-del-roc-o","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine trains the immune system to recognize and attack SARS-CoV-2 virus by presenting viral antigens or genetic instructions to produce them. Used for Prevention of COVID-19 infection and severe disease.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}